Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 615

1.

Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?

Barbui T, Carobbio A, Ferrari A.

Blood Adv. 2019 Dec 10;3(23):3951-3952. doi: 10.1182/bloodadvances.2019001159. No abstract available.

PMID:
31805188
2.

Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study).

Brucato A, Ferrari A, Tiraboschi M, Zucchi A, Cogliati C, Torzillo D, Dentali F, Tavecchia L, Gessi V, Squizzato A, Moretti S, Permunian ET, Carobbio A, Pasina L, De Stefano F, Tombetti E, Cumetti D, Tognoni G, Barbui T.

Eur J Intern Med. 2019 Nov 19. pii: S0953-6205(19)30355-3. doi: 10.1016/j.ejim.2019.10.016. [Epub ahead of print]

3.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Lurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2019 Nov 12. doi: 10.1002/ajh.25677. [Epub ahead of print]

PMID:
31721282
4.

Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin.

Barbui T, Ghirardi A, Vannucchi AM, Marchetti M, De Stefano V; MPN-K authors.

Leukemia. 2019 Nov 7. doi: 10.1038/s41375-019-0616-4. [Epub ahead of print] No abstract available.

PMID:
31700081
5.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25644. [Epub ahead of print] No abstract available.

PMID:
31588594
6.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.

Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.

PMID:
31515250
7.

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.

Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, Barosi G.

Blood Cancer J. 2019 Aug 8;9(8):61. doi: 10.1038/s41408-019-0225-5.

8.

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.

Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM.

Am J Hematol. 2019 Jun 9. doi: 10.1002/ajh.25555. [Epub ahead of print] No abstract available.

PMID:
31179561
9.

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T.

Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211. Review.

10.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

11.

Facing erythrocytosis: Results of an international physician survey.

Rumi E, McMullin MF, Harrison C, Ellis MH, Barzilai M, Sarid N, Mesa R, Paoli C, Angona A, Sant'Antonio E, Ferretti VV, Cavalloni C, Casetti IC, Trotti C, Barbui T.

Am J Hematol. 2019 May 31. doi: 10.1002/ajh.25545. [Epub ahead of print] No abstract available.

PMID:
31148218
12.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.

Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.

Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.

PMID:
31142846
13.

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.

Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, Vannucchi AM, Barbui T.

Haematologica. 2019 Dec;104(12):2391-2399. doi: 10.3324/haematol.2019.221234. Epub 2019 May 23.

14.

Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study.

Gritti P, Zangari R, Carobbio A, Zucchi A, Lorini FL, Ferri F, Agostinis C, Lanterna LA, Brembilla C, Foresti C, Barbui T, Biroli F.

World Neurosurg. 2019 Aug;128:e531-e540. doi: 10.1016/j.wneu.2019.04.190. Epub 2019 Apr 30.

PMID:
31048051
15.

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.

Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA.

Hematol Oncol. 2019 Aug;37(3):240-252. doi: 10.1002/hon.2622. Epub 2019 Jun 20. Review.

PMID:
31013548
16.

Comments on pre-fibrotic myelofibrosis and how should it be managed.

Barbui T, Thiele J, Gisslinger H, Orazi A, Vannucchi AM, Gianelli U, Beham-Schmid C, Tefferi A.

Br J Haematol. 2019 Jul;186(2):358-360. doi: 10.1111/bjh.15840. Epub 2019 Mar 7. No abstract available.

PMID:
30847907
17.

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM.

Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9. No abstract available.

18.

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.

De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y.

19.

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms.

Barbui T, Finazzi G, Vannucchi AM, De Stefano V.

Blood Cancer J. 2018 Nov 7;8(11):103. doi: 10.1038/s41408-018-0143-y. No abstract available.

20.

Prefibrotic myelofibrosis: treatment algorithm 2018.

Finazzi G, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Nov 7;8(11):104. doi: 10.1038/s41408-018-0142-z. Review.

21.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

22.

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2019 Jan;94(1):133-143. doi: 10.1002/ajh.25303. Epub 2018 Nov 9.

PMID:
30281843
23.

Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al.

Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T.

Leukemia. 2018 Dec;32(12):2727-2728. doi: 10.1038/s41375-018-0259-x. Epub 2018 Sep 28. No abstract available.

PMID:
30267006
24.

Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.

Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G.

Leukemia. 2018 Sep;32(9):2077-2081. doi: 10.1038/s41375-018-0199-5. Epub 2018 Jun 28. No abstract available.

PMID:
29955128
25.

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.

Finazzi G, De Stefano V, Barbui T.

Blood Cancer J. 2018 Jun 26;8(7):64. doi: 10.1038/s41408-018-0100-9. Review.

26.

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.

De Stefano V, Finazzi G, Barbui T.

Blood Cancer J. 2018 Jun 26;8(7):65. doi: 10.1038/s41408-018-0101-8.

27.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
28.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

29.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

30.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

31.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

32.

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A.

Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. Review.

33.

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.

Marchetti M, Carobbio A, Capitoni E, Barbui T.

Am J Hematol. 2018 May;93(5):698-703. doi: 10.1002/ajh.25049. Epub 2018 Feb 10.

34.

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.

Ghirardi A, Carobbio A, Masciulli A, Barbui T.

Blood Cancer J. 2018 Jan 16;8(1):5. doi: 10.1038/s41408-017-0038-3. No abstract available.

35.

Polycythemia vera treatment algorithm 2018.

Tefferi A, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Jan 10;8(1):3. doi: 10.1038/s41408-017-0042-7. Review.

36.

Essential thrombocythemia treatment algorithm 2018.

Tefferi A, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8. Review.

37.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
38.

[Prospective assessment of the agreement of instruments for measuring the hospital nursing workload: the Swiss Method, the Karnofsky Performance Status Scale and the subjective perception of the nurses].

Casati M, Invernici A, Barbui T, Ghirardi A, Bonetalli A, Cesa S.

Assist Inferm Ric. 2017 Oct-Dec;36(4):179-188. doi: 10.1702/2817.28484. Italian.

PMID:
29200210
39.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
40.

Myeloproliferative Neoplasms.

Barbui T, Thiele J, Tefferi A.

N Engl J Med. 2017 Aug 31;377(9):894-5. doi: 10.1056/NEJMc1708485. No abstract available.

PMID:
28858464
41.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. No abstract available.

42.

Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit.

Buoro S, Manenti B, Seghezzi M, Dominoni P, Barbui T, Ghirardi A, Carobbio A, Marchesi G, Riva I, Nasi A, Ottomano C, Lippi G.

J Clin Pathol. 2018 Apr;71(4):330-335. doi: 10.1136/jclinpath-2017-204643. Epub 2017 Aug 20.

PMID:
28824010
43.

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G.

Am J Hematol. 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. Epub 2017 Jul 29.

44.

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian JJ, Gianelli U, Silver R, Mughal TI, Barbui T.

Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29.

45.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
46.

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F.

Eur J Haematol. 2017 Jul;99(1):36-41. doi: 10.1111/ejh.12887. Epub 2017 May 5.

PMID:
28370510
47.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group.

Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.

PMID:
28351937
48.

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.

Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2. Review. No abstract available.

49.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323. No abstract available.

PMID:
28248313
50.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

Supplemental Content

Loading ...
Support Center